New hope for stomach cancer: drug cocktail targets tough tumors
NCT ID NCT07332533
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new drug called KN026, combined with chemotherapy and an immunotherapy (enlonstobart), as a first treatment for people with HER2-positive advanced stomach cancer that cannot be removed by surgery. About 490 participants will be split into groups to compare this new combo against the current standard treatment (trastuzumab plus chemotherapy with or without pembrolizumab). The goal is to see if the new combination shrinks tumors better and keeps cancer from growing longer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- KN026 (a drug targeting HER2) combined with chemotherapy and enlonstobart (an immunotherapy)
- What this could lead to
- If successful, this could offer a more effective first-line treatment option for people with HER2-positive advanced gastric cancer, potentially improving tumor shrinkage and delaying disease progression.
- What could go wrong
- This is an early-stage trial (phase II/III) that has not yet started recruiting. The combination may cause more side effects, and it is uncertain whether it will outperform existing standard therapies like trastuzumab plus pembrolizumab.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Targeted antibody combo aims to shrink HER2-Positive stomach cancers before surgery
- Experimental HER2 cancer drug trial halted early
- New radioactive tracer could spot hidden HER2 cancers
- New drug cocktail aims to tackle tough stomach cancer
- New cocktail targets Hard-to-Treat stomach cancer
- New drug cocktail targets Hard-to-Treat HER2 cancers